



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Ref: PDL: AUGUST: 2017

Date: 14.08.2017

The National Stock Exchange of India Limited,
Exchange Plaza,
Plot no. C/1, G Block,
Bandra-Kurla Complex,
Bandra (East)
Mumbai (Maharashtra)

SUBJECT: SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR THE
QUARTER ENDED ON 30TH JUNE, 2017

Sir/Madam

Pursuant to Regulation 29 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Unaudited Financial Results of the Company for the Quarter ended on 30th June, 2017 as approved by the Board of Directors in its meeting held on Monday, the 14th day of August, 2017, along with the Report of the Auditors.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

For & On Behalf Of Parabolic Drugs Limited
Sincerely

For Parabolic Drugs Limited

Ishrat Gill

Company Secretary

S. K. BANSAL & CO.

CHARTERED ACCOUNTANTS

Kothi No. : 3193, Sector 28-D,

Chandigarh-160 002

E-mail : skbansalandco@gmail.com

Website : www.cabansals.in

Phones : Off. : 0172-4629193

2657202

2657644

Fax : 0172-2655954

PAN : AAPFS1400D

S. Tax No. : AAPFS1400DST001

Limited Review Report to the Board of Directors

We have reviewed the accompanying statement of unaudited financial results as enclosed of **M/s Parabolic Drugs Limited having Registered Office at SCO 99-100, Top Floor, Sector-17B, Chandigarh for the Quarter/three months ended 30th June 2017**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above and **subject to Annexure-A**, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chandigarh;

Dated: 14th August 2017

**FOR S.K. BANSAL & CO.,
CHARTERED ACCOUNTANTS
FRN No.002222N**




(S.K. Bansal)

Membership No: 013147

Notes on the Un audited financial results of M/s Parabolic Drugs Limited


For the Quarter/Three months ended 30th June 2017

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Depreciation has been provided for on pro-rata basis as per Companies Act, 2013.
3. Figures of the previous year/Quarter/Three months have been rearranged/regrouped wherever considered necessary.
4. Other operating income for the three months ended 30 June 2017 includes Rs.3.67 crores which is subject to reconciliation and confirmation.
5. Net Sales for the quarter ended 30th June 2017 includes stock transfer of Rs.4.19 crores made during the quarter on consignment basis.

Chandigarh;
Dated: 14th August 2017

FOR S.K. BANSAL & CO.,
CHARTERED ACCOUNTANTS
FRN No.002222N




(S.K.Bansal)
Membership No: 013147

Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh

Statement of Un-audited Financial Results for the Quarter Ended 30th June 2017

(Rs. In Crore)

Sr. No.	Particulars	Quarter ended			Year Ended
		30.06.2017	31.03.2017	30.06.2016	31.03.2017
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations	15.33	19.89	10.85	69.12
II	Other income	4.48	2.46	0.30	8.85
III	Total Revenue (I+II)	19.81	22.35	11.15	77.97
IV	Expenses:				
	Cost of materials consumed	14.02	19.59	11.94	64.08
	Purchases of Stock-in-Trade	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(0.03)	5.39	26.25	27.86
	Employees benefits expense	2.37	2.30	1.74	8.47
	Finance costs	2.56	(82.80)	31.89	9.91
	Depreciation and amortization expense	8.65	13.34	13.38	53.49
	Other expenses	4.41	6.05	3.26	19.19
	Total expenses	31.97	(36.14)	88.46	182.99
V	Profit before exceptional and extraordinary items and tax (III-IV)	(12.16)	58.48	(77.31)	(105.02)
VI	Exceptional Items	-	-	-	-
VII	Profit before extraordinary items and tax (V - VI)	(12.16)	58.48	(77.31)	(105.02)
VIII	Extraordinary items	-	-	-	-
IX	Profit before tax (VII- VIII)	(12.16)	58.48	(77.31)	(105.02)
X	Tax expenses:	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	0.45	0.73	-	3.05
XI	Profit (Loss) for the period from continuing operations (IX-X)	(12.60)	57.75	(77.31)	(108.07)
XII	Profit/(loss) from discontinuing operations	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(12.60)	57.75	(77.31)	(108.07)
XVI	Paid-up Equity share capital (Face value of Rs.10/- each)				
	- Issued and Subscribed Capital	61.89	61.89	61.89	61.89
	- Share Forfeited Amount	-	-	-	-
XVII	Reserves excluding revaluation reserves	-	-	-	(932.60)
XVIII	Earning Per Share (EPS) (Not Annualized)				
	a) Basic and diluted EPS before Extraordinary Items (In Rs.)	(2.04)	9.33	(12.49)	(17.46)
	b) Basic and diluted EPS after Extraordinary Items (In Rs.)	(2.04)	9.33	(12.49)	(17.46)



Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B, Chandigarh - 160 017 (India) Tel. : +91-172-3914646, 3914647

Works - I : Village Sundhran, P.O. Mubarakpur, Dera Bas Distt. Mohali, Punjab, India
website : www.parabolicdrugs.com



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Notes :

1. The above quarterly results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 14th August 2017 and the same have been reviewed by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
2. During the period under review, the company has incurred loss owing to the unfavorable market conditions, interest burden and economic stress, the company has witnessed an erosion in the margins of key products.
3. The promoters' shareholding (22619927 Equity shares) has been pledged pursuant to the terms of CDR package.
4. There is not more than one reportable segment, hence, information as per AS-17 is not required to be disclosed.
5. Figures of the previous year / period have been rearranged/regrouped wherever considered necessary.
6. During the quarter ended 30th June, 2017, most of Banks have not charged interest due to NPA Status of Loan Accounts. Hence no Provision for interest for the quarter ended 30th June, 2017 on these loans has been made on the belief that such interest would be waived at the time of final settlement.

Place : Chandigarh

Date : 14th August 2017

For Parabolic Drugs Limited

Pranav Gupta
Managing Director

